CRISPR Therapeutics’ Pipeline Continues to Make Progress; FVE Remains $119; Shares Very Undervalued

CRISPR Therapeutics posted fourth-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. We maintain our fair value estimate of $119 per share and view the stock as very undervalued, currently trading in 5-star territory. As a clinical-stage biotech company, CRISPR Therapeutics provides long-term investors who possess a high degree of risk tolerance with pure play exposure to novel gene editing technology to treat severe, genetic diseases.